Retatrutide clears first late-stage Type 2 diabetes trial, showing strong A1c and weight results
On March 19, 2026, Eli Lilly reported that retatrutide — its next‑generation obesity therapy — met the primary and key secondary endpoints in a first late‑stage trial among people with Type 2 diabetes. In the 40‑week study, retatrutide lowered hemoglobin A1c by an average of 1.7%–2.0% across doses versus placebo and produced substantial weight loss … Read more